美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Portola Pharmaceuticals Inc.

18.03

0.0000

成交量：- -

成交額：- -

市值：14.16億

市盈率：-4.76

高：18.03

開：18.03

低：18.03

收：18.03

52周最高：31.73

52周最低：5.31

股本：7,851.73萬

流通股本：7,322.61萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.7842

每股收益(LYR):-4.0621

淨資產收益率：-462.25%

總資產收益率：-30.59%

市淨率：19.65

市盈率(LYR):-4.44

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Portola Pharmaceuticals Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.portola.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Portola Pharmaceuticals, Inc.是一家生物製藥企業。公司致力於在血栓疾病以及其他血液疾病和發炎病症領域研發新的療法，同時將該療法商業化。該療法主要用於當前沒有或認證療法選擇有限的病人。公司於2003年9月在特拉華州註冊成立。公司總部以及業務範圍在加利福尼亞州的南舊金山市，並以一個部門生產經營。公司兩個主要項目用於解決血栓疾病和血凝塊方面的問題。公司主要化合物是新型口服每日一次的貝曲西班，它是處於第三研發階段凝血因子Xa的抑製劑，主要用於急性內科疾病患者靜脈血栓栓塞的長期預防或預防性療法。公司第二主要的候選研發藥物是正處於概念取證階段的PRT4445，它是一個主要用於逆轉抗凝血生理活動的重組蛋白，該藥主要用於使用抗凝血因子抑製劑治療的患有不可控流血疾病或經歷急診外科手術的患者。公司第三種候選產品PRT2070是一種可口服的激酶抑製劑，該藥物主要用於血液系統疾病、血液疾病、癌症及其他發炎類疾病。公司第四候選產品是 PRT2607，該藥物由公司合作夥伴百健艾迪股份有限公司（Biogen Idec Inc.）開發研製，主要用於發炎類疾病。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PTLA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"PTLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","market":"US","secType":"STK","nameCN":"Portola Pharmaceuticals Inc.","latestPrice":18.03,"timestamp":1593633600000,"preClose":18.03,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":73226120,"shares":78517282,"eps":-3.784152,"marketStatus":"停牌","change":0,"latestTime":"03-23 14:24:53 EDT","open":18.03,"high":18.03,"low":18.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.784152,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1369195200000,"exchange":"NASDAQ","adjPreClose":18.03,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","floatShares":73226120,"roa":"-30.59%","roe":"-462.25%","lyrEps":-4.062079,"shares":78517282,"dividePrice":0,"high":18.03,"amplitude":0,"preClose":18.03,"low":18.03,"week52Low":5.31,"pbRate":"19.65","week52High":31.73,"institutionHeld":0,"latestPrice":18.03,"eps":-3.784152,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.784152,"open":18.03,"prevYearClose":23.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-11","symbol":"PTLA","fiscalQuarterEnding":"2020/03","expectedEps":-0.74,"name":null,"time":"盤後","type":"earning","dateTimestamp":1589169600000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2020-02-26","symbol":"PTLA","fiscalQuarterEnding":"2019/12","expectedEps":-0.89,"name":null,"time":"盤後","type":"earning","dateTimestamp":1582693200000,"reportTimeType":"post","actualEps":-1.24},{"date":"2019-11-05","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.82,"defaultRemindTime":1572987600000,"name":null,"time":"盤後","dateTimestamp":1572930000000,"actualEps":null},{"date":"2019-08-07","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-1.05,"defaultRemindTime":1565208000000,"name":null,"time":"盤後","dateTimestamp":1565150400000,"actualEps":-1.61},{"market":"US","date":"2019-05-08","symbol":"PTLA","fiscalQuarterEnding":"2019/03","expectedEps":-1.02,"name":null,"time":"盤前","type":"earning","dateTimestamp":1557288000000,"reportTimeType":"pre","actualEps":-1.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTLA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTLA","date":"2020-07-02","current":-4.764608,"percent":0.525692,"low":-8.397919,"twenty":-7.298314,"median":-5.390954,"eighty":-3.580615,"high":-1.552673,"avg":-5.298922,"sd":2.018062,"marketCap":1415666594},"quantilePoints":[],"updateTime":1774254144916},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.portola.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Portola Pharmaceuticals, Inc.是一家生物製藥企業。公司致力於在血栓疾病以及其他血液疾病和發炎病症領域研發新的療法，同時將該療法商業化。該療法主要用於當前沒有或認證療法選擇有限的病人。公司於2003年9月在特拉華州註冊成立。公司總部以及業務範圍在加利福尼亞州的南舊金山市，並以一個部門生產經營。 公司兩個主要項目用於解決血栓疾病和血凝塊方面的問題。公司主要化合物是新型口服每日一次的貝曲西班，它是處於第三研發階段凝血因子Xa的抑製劑，主要用於急性內科疾病患者靜脈血栓栓塞的長期預防或預防性療法。公司第二主要的候選研發藥物是正處於概念取證階段的PRT4445，它是一個主要用於逆轉抗凝血生理活動的重組蛋白，該藥主要用於使用抗凝血因子抑製劑治療的患有不可控流血疾病或經歷急診外科手術的患者。公司第三種候選產品PRT2070是一種可口服的激酶抑製劑，該藥物主要用於血液系統疾病、血液疾病、癌症及其他發炎類疾病。公司第四候選產品是 PRT2607，該藥物由公司合作夥伴百健艾迪股份有限公司（Biogen Idec Inc.）開發研製，主要用於發炎類疾病。","exchange":"NASDAQ","name":"Portola Pharmaceuticals Inc.","nameEN":"Portola Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":null}}